New drug cocktail shows promise for tough liver cancer
NCT ID NCT06986785
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called BL-B01D1, alone or with other cancer drugs, in 74 people with advanced liver cancer that has spread. The goal is to see if these combinations can shrink tumors and how safe they are. Participants will receive the drugs through an IV or as pills over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug that targets cancer cells) combined with lenvatinib, finotonlimab (a PD-1 inhibitor), and/or bevacizumab
What this could lead to
If successful, this could provide new treatment options for people with advanced liver cancer that has not responded to other therapies.
What could go wrong
This is an early Phase 2 trial with only 74 participants, so results may not apply to everyone. The drug combinations may cause side effects and may not shrink tumors or extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact